Name Index

A
Addis, M. E., 40, 41
Aesop, 1
Aguilar, C., 171
Ahn, H., 32, 40
Albee, G., 21
Alimohamed, S., 41
Anastasi, A., 92
Anderson, H., 122
Anderson, T., 114
Andrews, A. A., 87
Angell, M., 154
Anker, M., 93, 108, 109, 111
Anthony, S. B., 18
Antonacci, D. O., 156, 168, 171
Arcona, A., 156
Arneill, A. B., 88
Arnow, B., 162
Arthus, N. M., 23
Asarnow, J. R., 156
Asay, T. P., 9, 33–35, 37, 38, 51, 63

B
Bachelor, A., 35, 36, 64, 65, 85, 89, 193
Badgett, R., 171
Barber, J., 90, 92
Barens, A. W., 90, 91
Barley, D. E., 84
Barondes, S., 166, 167
Barrett, W., 120
Barry, E., 148
Bassman, R., 213, 217
Beck, A., xviii
Beckham, R., 173
Belar, C., 7
Benson, K., 32, 40
Berg, I. K., 58
Bergin, A. E., 42, 93
Bergstrom, D., 28
Berman, J. S., 173, 174
Berman, P., 2
Berthelot, J., 4
Beutler, L. E., 26, 27, 29, 41, 172
Bevilacqua, L. J., 183
Birmaher, B., 151, 156, 162
Blaske, D., 43
Blatt, S. J., 89
Bobart, A., 34, 51, 198
Boles, M., 148
Bordin, E. S., 35, 64, 90
Borduin, C., 43, 44
Bornstein, R. F., 152, 171
Borus, J., 24
Bosley, S., 162
Breggin, P., 158–162
Brent, D. A., 151, 156
Brockman, P., 121
Brown, E., 151
Brown, G. S., 85
Brown, J. S., 88–90, 92–94, 96, 99, 117
Browne, T., 1
Burlingame, G. M., 86–88
Burr, R., 49

C
Carlsson, A., 166, 167
Carlson, G., 162
Carroll, K. M., 36, 89
Carroll, L., 32
NAME INDEX

Carson, R. C., 24
Castonguay, L. G., 40
Cervantes, M., 81
Chalk, M., 14, 47, 94, 96, 117
Chiquette, E., 171
Ciotti, M., 5
Clarke, G. N., 156
Clarkin, J., 26, 27, 229
Claud, D., 88, 89, 92, 93, 94
Cleeland, C. S., 88
Clement, P. W., 14
Clouse, G. C., 86, 88
Coates D., 121
Cohen, D., 156, 161, 162
Cohn, E., 121
Coleman, S., 119
Collins, J. F., 26, 32, 72
Cone, L., 43
Connors, G. J., 36, 89
Conrad, J., 182
Conte, H. R., 174
Cornell, J. E., 5, 171
Cross, H., 28
Crowley, S. L., 156
Cummings, N. A., 2, 5
Curry, J. F., 156
D
Daley, D., 90, 92
Dannon, P. N., 88
Danton, W. G., 168
Dardennes, R. M., 153
Dattilio, F. M., 183
Davies, M., 24
de Shazer, S., 11, 56, 57, 96, 143
DeBernardo, C., 28
DeNelsky, G. Y., 168
DeRubeis, R. J., 172
Devlin, A. S., 88
Dewey, J., 117
DiClemente, C., 36, 89
Dietrich, A., 5
Diller, K. H., 148, 149
Dobson, K., 40
Docherty, J. P., 26, 32, 72
Dolan, C., 173
Dolberg, O. T., 88
Donovan D. M., 36, 89
dosReis, S., 30, 148, 163
Dreis, S., 2, 26, 32, 83, 85–86, 96, 98, 117
Dunner, D. L., 162
Duriez, S., 1
E
Elkin, I., 26, 32, 36, 72, 89
Emslie, G. J., 151–155, 161, 175
Epston, D., 127
Erickson, M. H., 10–12, 121, 125, 126
Ernest, D. E., 151
Eron, J., 127
Eshun, S., 15
Evan, C., 153
F
Fiester, S. J., 26, 32, 72
Finch, A. E., 15
First, M., 24
Fisch, R., 121
Fisher, R. L., 151, 162
Flexner, J. T., 13
Fogel, B., 169
Frank, A., 90, 92
Frank, E., 174
Frank, J. B., 121
Frank, J. D., 29, 33, 121
Freud, S., 7, 23, 37, 117, 187
Fucci, B., 43
G
Garb, H. N., 24
Gardner, J. F., 148
Garfield, S., 26
Garfinkel, R., 156
Gaston, L., 71, 90
Gelenberg, A. J., 162
Geller, B., 162
Georgaca, E., 187
Ger, L. P., 88
Gergen, K. E., 179
Gesten, E. L., 3
Gibbon, M., 24
Gilman, A. G., 168
Gingerich, W., 56, 57, 96
Glass, D. R., 26, 32, 72
Goldfried, M. R., 40
Goldman, A., 43
Gollan, J., 40
Goolishian, H., 122
Gordon, J. S., 168
Gortner, D., 40
Grawe, K., 36
Greenberg, L. S., 43, 90
Greenberg, M. D., 152, 171
Greenberg, R. P., 147, 152, 153, 168, 170–173
Greenhouse, J. B., 174
Grochocinski, V., 174
Grube, J., 28
Grunhaus, L., 88

H
Haas, E., 83, 84
Hagino, O. R., 162
Hales, R., 169
Haley, J., 127, 198
Hansen, N. B., 83, 86, 88
Hanych, J. M., 2
Harding, C., 27
Hardman, J. G., 168
Hardy, R., 172
Hargrave, G. E., 14
Harper, D., 187
Harwood, T. M., 41
Hatcher, R. L., 90, 91
Hatgis, C., 41
Hawkins, E. J., 15, 83, 84, 95, 117
Hayes, A. M., 40
Healy, D., 29, 167, 169
Heaton, K., 64
Heiligenstein, J. H., 151
Held, B. S., 121, 122
Henggeler, S., 43
Heracleitus, 56
Hiatt, D., 14
Hill, C. E., 64, 87, 108, 110
Hill, R. D., 83, 84
Ho, S. T., 88
Hoch, P., 120
Hollon, S. D., 172
Holloway, J. D., 29
Hoog, S. L., 151
Horvath, A. O., 35, 36, 65, 85, 89, 90, 193
Howes, M., 24
Hubble, M. A., 2, 7, 9, 12, 19, 27, 28, 31, 33, 34, 38, 71, 72, 78, 79
Hughes, C. W., 153
Hunsley, J., 43
Huxley, T. H., 21, 31

I
Iancu, I., 88
Imber, S. D., 173

J
Jackson, G., 147
Jacobson, J. G., 151
Jacobson, N., 40
Jaycox, L. H., 156
Jensen, P. S., 148, 159
John Paul, Pope, 77
Johnson, L. D., 3, 15, 85, 89, 90, 93, 117
Johnson, S. M., 42, 43, 90–92

K
Kadera, S. W., 87
Kane, J., 24
Karasu, T. B., 174
Karon, B., 198
Karuza, J., 121
Kaspar, 178
Kaufman, J., 151
Kaye, J., 179
Kelley, L., 119
Keller, M. B., 162, 174
Kelly, G., 120
Kendell, R., 25
Kennedy, J. E., 3
Kesey, K., 181
<table>
<thead>
<tr>
<th>NAME INDEX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kidder, L., 121</td>
</tr>
<tr>
<td>Kiesler, C., 4, 5</td>
</tr>
<tr>
<td>Kinchin, K., 147</td>
</tr>
<tr>
<td>Kipras, A., 156</td>
</tr>
<tr>
<td>Kirk, S. A., 24, 25, 28–30, 187</td>
</tr>
<tr>
<td>Kirsch, I., 168, 171, 172</td>
</tr>
<tr>
<td>Klein, D. N., 162</td>
</tr>
<tr>
<td>Klein, R. G., 162</td>
</tr>
<tr>
<td>Kline, N., 165, 166</td>
</tr>
<tr>
<td>Koerner, K., 40</td>
</tr>
<tr>
<td>Koplewicz, H., 162</td>
</tr>
<tr>
<td>Kopp, S. G., 119</td>
</tr>
<tr>
<td>Kopte, S. M., 83, 84, 96, 117</td>
</tr>
<tr>
<td>Kowatch, R. A., 153</td>
</tr>
<tr>
<td>Krause, M. S., 83, 84, 96, 117</td>
</tr>
<tr>
<td>Kremer, T. G., 3</td>
</tr>
<tr>
<td>Krupnick, J. L., 36, 89</td>
</tr>
<tr>
<td>Kupfer, D. J., 174</td>
</tr>
<tr>
<td>Kusumakar, V., 162</td>
</tr>
<tr>
<td>Kutchins, H., 24, 25, 28–30, 187</td>
</tr>
<tr>
<td>L</td>
</tr>
<tr>
<td>Laird, N. M., 171</td>
</tr>
<tr>
<td>Lambert, M. E., 42, 93</td>
</tr>
<tr>
<td>Lawrence, V., 171</td>
</tr>
<tr>
<td>Lawson, D., 56, 96</td>
</tr>
<tr>
<td>Leber, W. R., 26, 32, 72</td>
</tr>
<tr>
<td>Lee, L., 82</td>
</tr>
<tr>
<td>Lee, S., 171</td>
</tr>
<tr>
<td>LeFever, G., 156, 159, 160</td>
</tr>
<tr>
<td>Leighton, A. H., 171</td>
</tr>
<tr>
<td>Leo, J., 156, 160</td>
</tr>
<tr>
<td>Levitt, T., 81–83</td>
</tr>
<tr>
<td>Lewisohn, P. M., 156</td>
</tr>
<tr>
<td>Limbird, L. E., 168</td>
</tr>
<tr>
<td>Lincoln, A., 12</td>
</tr>
<tr>
<td>Longabaugh, R., 36, 89</td>
</tr>
<tr>
<td>Luborsky, L., 32, 90, 92</td>
</tr>
<tr>
<td>Lueger, R. J., 84</td>
</tr>
<tr>
<td>Lund, T., 127</td>
</tr>
<tr>
<td>Lurie, P., 155</td>
</tr>
<tr>
<td>Luther, M., 171</td>
</tr>
<tr>
<td>Lutz, W., 83, 85, 108, 109</td>
</tr>
<tr>
<td>Lynch, F., 148</td>
</tr>
<tr>
<td>M</td>
</tr>
<tr>
<td>Mackey, P., 156</td>
</tr>
<tr>
<td>Madigan, S., 127</td>
</tr>
<tr>
<td>Magder, L., 148</td>
</tr>
<tr>
<td>Malik, M., 41</td>
</tr>
<tr>
<td>Malin, M. S., 84</td>
</tr>
<tr>
<td>Mann, B., 43</td>
</tr>
<tr>
<td>Marcus, S. C., 148</td>
</tr>
<tr>
<td>Markowitz, J. C., 162</td>
</tr>
<tr>
<td>Masters, K., 86, 110</td>
</tr>
<tr>
<td>Matt, G. E., 41</td>
</tr>
<tr>
<td>McCafferty, J. P., 162</td>
</tr>
<tr>
<td>McCall, R., 91</td>
</tr>
<tr>
<td>McCullough, J. P., 162</td>
</tr>
<tr>
<td>McGuire, W., 7</td>
</tr>
<tr>
<td>McLaughlin, T., 187</td>
</tr>
<tr>
<td>Melton, G., 43</td>
</tr>
<tr>
<td>Messer, S., 37, 42</td>
</tr>
<tr>
<td>Meyer, G., 50</td>
</tr>
<tr>
<td>Michael, K. D., 156</td>
</tr>
<tr>
<td>Mill, J. S., 145</td>
</tr>
<tr>
<td>Miller, L., 28</td>
</tr>
<tr>
<td>Miller, S. D., 2, 7, 9, 15, 19, 27, 28, 31, 33, 34, 38, 47, 51, 58, 71, 72, 78, 79, 88–90, 92–94, 96–98, 117, 152, 183</td>
</tr>
<tr>
<td>Mitka, M., 163</td>
</tr>
<tr>
<td>Mohl, D. C., 185</td>
</tr>
<tr>
<td>Moncrieff, J., 170, 172</td>
</tr>
<tr>
<td>Mondin, G. W., 32, 40</td>
</tr>
<tr>
<td>Monson, R. R., 171</td>
</tr>
<tr>
<td>Moody, M., 32, 40</td>
</tr>
<tr>
<td>Moore, T. J., 168, 172</td>
</tr>
<tr>
<td>Moras, K., 83, 85, 108, 109</td>
</tr>
<tr>
<td>Moreau, D., 156</td>
</tr>
<tr>
<td>Morrell, B., 83, 84</td>
</tr>
<tr>
<td>Morris, J., xviii</td>
</tr>
<tr>
<td>Moyer, J., 36, 89</td>
</tr>
<tr>
<td>Moynihan, D., 121</td>
</tr>
<tr>
<td>Mufson, L., 156</td>
</tr>
<tr>
<td>Mulrow, C. D., 171</td>
</tr>
<tr>
<td>Murphy, J. J., 128</td>
</tr>
</tbody>
</table>
NAME INDEX

Murphy, J. M., 171
Murphy, M., 28
Musselman, D. L., 167
Mustard, C., 4

N
Nace, D. K., 2, 26, 32, 83, 85–86, 96, 98, 117
Najavits, L., 90, 92
Nathan K. I., 167, 168
Nathan, P. E., 39
Navarro, A. M., 41
Neimeyer, R. A., 173, 174
Nemeroff, C. B., 162, 167
Nicholls, S. S., 172
Nielsen, S. L., 15, 83, 84, 95, 117
Nies, A., 168
Nilsson, M., 151
Noble, S., 41
Noel, P. H., 171
Norcross, J., 2, 119, 120
Nutt-Williams, E., 64

O
Oakes, R., 162
O’Connor, E., 159
Ogles, B., 14, 41, 86, 96, 110
Okishi, J. C., 15
Olsson, M., 148, 149
Orlinsky, D. E., 36, 83, 84, 96, 117
Orwell, G., 10, 44
Osler, W., 164
Ostrom, J., 50

P
Papatheodorou, G., 162
Parker, I., 187
Parks, B. K., 36
Parloff, M. B., 9, 26, 32, 72
Pascal, B., 126
Pelham, W., 157–159
Peller, J., 58, 127
Phillips, G., 41
Pilkonis, P. A., 26, 32, 36, 72, 89
Plutchik, R., 174
Polak, D., 88
Pope, H., 24

Q
Quinlan, D. M., 89

R
Rabasca, L., 2
Rabinowitz, V., 121
Rall, T., 168
Ramirez, G., 171
Rao, S., 169
Raue, P., 40
Reynolds, L., 90, 92, 93
Rhodes, R. H., 64
Richardson, W. S., 171
Riddle, M., 30, 148, 163
Riley, W. T., 15
Rintelenmann, J., 40, 153
Robinson, L. A., 173, 174
Ronnestad, M. H., 36
Rosenhan, D. L., 27
Rosenzweig, S., 32, 33, 52
Rossi, E. L., 121
Rost, K., 5
Rounsaville, B., 24
Rush, A. J., 40, 153
Rusk, G., 65, 79
Russell, J. M., 162
Ryan, N. D., 151, 162

S
Sack, W. H., 162
Safer, S. J., 30, 148, 163
Salovey, P., 27
Saltzman, N., 120
Sanchez, L., 3–5
Sanderson, W. C., 15
Sapirstein, G., 171, 172
Sasich, L. D., 155
Schappert, S., 5
Schatzberg, A. F., 167
Schiffer, R., 169
Schindler, D., 43
Scoboria, A., 168, 172
Scott, J., 7
Segal, L., 121
Shadish, W. R., 41
Shaha, S. H., 3, 85, 117
Shapiro, D., 40
<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shea, M.</td>
<td>173</td>
</tr>
<tr>
<td>Shea, T.</td>
<td>26, 32, 72</td>
</tr>
<tr>
<td>Shelton, R. C.</td>
<td>172</td>
</tr>
<tr>
<td>Shoemaker, W.</td>
<td>28</td>
</tr>
<tr>
<td>Simmens, S.</td>
<td>36, 89</td>
</tr>
<tr>
<td>Singer, B.</td>
<td>32</td>
</tr>
<tr>
<td>Siobud-Dorocant, E.</td>
<td>153</td>
</tr>
<tr>
<td>Siqueland, L.</td>
<td>90, 92</td>
</tr>
<tr>
<td>Sluzki, C.</td>
<td>179</td>
</tr>
<tr>
<td>Smart, D. W.</td>
<td>15, 83, 84, 95, 117</td>
</tr>
<tr>
<td>Smith, L.</td>
<td>43</td>
</tr>
<tr>
<td>Snyder, S.</td>
<td>166</td>
</tr>
<tr>
<td>Sobol, A. M.</td>
<td>171</td>
</tr>
<tr>
<td>Soeken, K.</td>
<td>148</td>
</tr>
<tr>
<td>Solovey, A.</td>
<td>65, 79</td>
</tr>
<tr>
<td>Sorrell, R.</td>
<td>14, 47, 94, 96, 117</td>
</tr>
<tr>
<td>Sotsky, S. M.</td>
<td>89, 173</td>
</tr>
<tr>
<td>Sparks, J. A.</td>
<td>11, 19, 88, 89, 92, 93, 94, 97–99, 108, 110, 114, 118, 152, 183, 200</td>
</tr>
<tr>
<td>Spitzer, R.</td>
<td>24</td>
</tr>
<tr>
<td>Stamm, K.</td>
<td>171</td>
</tr>
<tr>
<td>Stich, F.</td>
<td>32, 40</td>
</tr>
<tr>
<td>Stiles, W.</td>
<td>40</td>
</tr>
<tr>
<td>Stowell-Smith, M.</td>
<td>187</td>
</tr>
<tr>
<td>Strauss, D.</td>
<td>27</td>
</tr>
<tr>
<td>Strober, M.</td>
<td>162</td>
</tr>
<tr>
<td>Strosahl, K.</td>
<td>4</td>
</tr>
<tr>
<td>Sun, W. Z.</td>
<td>88</td>
</tr>
<tr>
<td>Swank, H.</td>
<td>22</td>
</tr>
<tr>
<td>Sweeney, M.</td>
<td>162</td>
</tr>
<tr>
<td>Symonds, B. D.</td>
<td>36</td>
</tr>
<tr>
<td>Talbott, J.</td>
<td>169</td>
</tr>
<tr>
<td>Talebi, H.</td>
<td>41</td>
</tr>
<tr>
<td>Tallman, K.</td>
<td>34, 51, 198</td>
</tr>
<tr>
<td>Taylor, P.</td>
<td>168</td>
</tr>
<tr>
<td>Terranova, R. D.</td>
<td>2</td>
</tr>
<tr>
<td>Thase, M. E.</td>
<td>162, 174</td>
</tr>
<tr>
<td>Thompson, B.</td>
<td>64</td>
</tr>
<tr>
<td>Tomiak, M.</td>
<td>4</td>
</tr>
<tr>
<td>Tompson, M. C.</td>
<td>156</td>
</tr>
<tr>
<td>Torrey, E.</td>
<td>120, 121</td>
</tr>
<tr>
<td>Trivedi, M. H.</td>
<td>162, 171</td>
</tr>
<tr>
<td>Truax, P.</td>
<td>40</td>
</tr>
<tr>
<td>Turk, D.</td>
<td>27</td>
</tr>
<tr>
<td>Turner, S.</td>
<td>3–5</td>
</tr>
<tr>
<td>Umphress, V.</td>
<td>6, 88</td>
</tr>
<tr>
<td>Valenstein, E.</td>
<td>169</td>
</tr>
<tr>
<td>Vanderbos, G.</td>
<td>198</td>
</tr>
<tr>
<td>Vandiver, W. D.</td>
<td>97</td>
</tr>
<tr>
<td>Vermeersch, D. A.</td>
<td>15, 83, 84, 86–88, 95, 117</td>
</tr>
<tr>
<td>Vitiello, B.</td>
<td>161</td>
</tr>
<tr>
<td>Wade, W. A.</td>
<td>41</td>
</tr>
<tr>
<td>Wagner, K. D.</td>
<td>149, 151, 154, 162</td>
</tr>
<tr>
<td>Walkup, J. T.</td>
<td>150, 160–163</td>
</tr>
<tr>
<td>Walter, J.</td>
<td>58, 127</td>
</tr>
<tr>
<td>Wampold, B. E.</td>
<td>9, 32, 34, 36–38, 40, 42, 43, 47, 63</td>
</tr>
<tr>
<td>Wang, M. S.</td>
<td>88</td>
</tr>
<tr>
<td>Washington, G.</td>
<td>12–14</td>
</tr>
<tr>
<td>Watkins, J. T.</td>
<td>26, 32, 36, 72, 89</td>
</tr>
<tr>
<td>Watzlawick, P.</td>
<td>23, 121, 127</td>
</tr>
<tr>
<td>Weakland, J.</td>
<td>121</td>
</tr>
<tr>
<td>Weinberg, W. A.</td>
<td>40, 153</td>
</tr>
<tr>
<td>Weiner-Davis, M.</td>
<td>56, 57, 96</td>
</tr>
<tr>
<td>Weiss, B.</td>
<td>172</td>
</tr>
<tr>
<td>Weissman, M. M.</td>
<td>148, 156</td>
</tr>
<tr>
<td>Weller, E. B.</td>
<td>162</td>
</tr>
<tr>
<td>Wessely, S.</td>
<td>172</td>
</tr>
<tr>
<td>Whipple, J. L.</td>
<td>15, 83–84, 95, 117</td>
</tr>
<tr>
<td>Whitaker, R.</td>
<td>187, 198</td>
</tr>
<tr>
<td>White, M.</td>
<td>127</td>
</tr>
<tr>
<td>Wild, K. V.</td>
<td>174</td>
</tr>
<tr>
<td>Wile, D.</td>
<td>121</td>
</tr>
<tr>
<td>Wilford, J.</td>
<td>50</td>
</tr>
<tr>
<td>Williams, J.</td>
<td>24</td>
</tr>
<tr>
<td>Williams, J. W., Jr.</td>
<td>5, 171</td>
</tr>
<tr>
<td>Williams, R.</td>
<td>43</td>
</tr>
<tr>
<td>Williamson, D. E.</td>
<td>151</td>
</tr>
<tr>
<td>Willutzki, U.</td>
<td>36</td>
</tr>
<tr>
<td>Winters, N. C.</td>
<td>162</td>
</tr>
</tbody>
</table>
Wiser, S., 40
Wittchen, H., 24
Wolfe, B. E., 6
Wolfe, S. M., 155
Wong, E., 41
Woolston, J. L., 149

Y
Yanchar, S. C., 86, 88
Yudosky, S., 169

Z
Zablansky, A., 25
Zajecka, J., 162
Zanuck, D. F., 82
Zborowski, M. J., 171
Zeig, J. K., 10, 11
Zito, J. M., 30, 148, 163
Zubin, R., 27
Zuroff, D. C., 89
Zyzanski, S., 5
Subject Index

A
Aceylcholine, 166
ADHD. See Attention deficit hyperactivity disorder (ADHD)
Advil, 51
Aesop, 1, 5
Agency for Health Care Policy and Research, 171
Agitation, 166
Agoraphobia, 115–117
AIDS, 66–68
Alcoholism, 36
Alice's Adventures in Wonderland (Carroll), 32
Allegiance, 37, 42, 43
Alliance factors, 35–37
Alliance monitoring, 64–65
Alzheimer's Disease, 39
American Association of Marriage and Family Therapy (AAMFT), 13, 149
American Counseling Association (ACA), 13
American Healthcare Institute, 6
American Journal of Psychiatry, 25
American Psychiatric Association, 29, 39
American Psychological Association (APA), 2, 6, 7, 13, 15, 23, 24, 33, 39, 83, 159, 214
American Psychologist, 84
Amphetamine, 149. See also Medication
Amy (client), 44, 45
Antidepressant Era, The (Healy), 29
Antidepressants, 160, 164, 165, 170–175; and children, 151–152; and drug research, 152–156
Anxiety, 166
Assessment, client-directed, outcome-informed therapy, 186–192
Attention deficit hyperactivity disorder (ADHD), 149, 156, 157, 159, 160
Attribution creep, 27, 28
Axis II diagnosis, 29
B
Barbara (client), 112–113
Beck Depression Inventory, 152
Bible, 115
Bill (client), 138
Bioamine theories, 167–169
Biochemical imbalance, 165–167
Biogenic amine theory, 167
Biological fundamentalism, 180
Biological markers, 167–169
Biome theories, 167–169
Bipolar disorder, 39
Blaming the Brain (Valenstein), 169
Bloodletting, 10
Bob (client), 126
Borderline personality disorder (BPD), 8, 25, 30, 44
Boston Globe, 148
Boulder conference, 21
Bowen family therapy, 36, 37
Boys Don't Cry (cinema), 22
BPD. See Borderline personality disorder (BPD)
C
California Psychotherapy Alliance Scales, 90
Case writing, 192
Catecholamine depletion, 166
CBSC. See Change-by-session curve (CBSC)
CBT. See Cognitive behavioral therapy (CBT)
Celexa, 164
Change, client's theory of, 19, 71–73; conversation, content, and change in, 122–124; learning and honoring, 73–75; and privileging client's voice, 126–145; and selection of content, 124–126; in tradition, 120–126; trusting, 145–146
Change focus: and becoming change focused, 56–63; and expanding change into heroic stories, 58–63; and listening for change, 56–58
Change-by-session curve (CBSC), 108–111
Child Outcome Rating Scale (CORS), 224
Child Session Rating Scale (CSRS), 225
Chlorpromazine, 166, 167
Cincinnati Bengals, 69
Circular causality, 187–188
Citalopram, 156
Client: accepting goals of, 68–70; as agent of change, 34–35; 51; casting, in heroic roles, 51–55; versus clinician ratings, 152; as critic of therapy performance, 63–71; engagement in therapy process, 16; feedback, 15, 19; Kim, 125–126; language of, 73; Linda, 111; Mike, 75–78; Molly, 49; partnering with, 97–117; self-report, 14
Client directed: becoming, 10–12, 49–80; versus theory driven, 19
Client-directed, outcome-informed therapy: and assessment, 186–192; goals for therapy, 192–194; interventions of, 194–198; model for, 184–186
Clients: Amy, 44; Barbara, 112–113; Bill, 138; Bob, 126; Emma, 201–211; Jan and Mark, 182–199; Joan, 59–63; Liz and Bob, 142–145; Maria, 16–18; Pat, 128–132; Robyn, 115–117; Sam, 65–68; Sarah, 69; Sean, 51; Stacy, 132–138; Steven, 113–115
Clinical trials, 31, 32
Clonidine, 148, 149. See also Medication
Coassessment, 190, 191
Cognitive behavioral therapy (CBT), 26, 32, 41, 44, 147
Common cause, 39
Common factors, 52; evolution and dangers of applying, 79–80
Competency, 13; client, 52, 53, 133; and effectiveness, 13; orientation, 127, 138; versus outcome, 14
Conflict avoidance pattern, 188, 189
Content, 122–124; selecting, 124–126
Continuing education requirement, 14
Conversation, 122–124
D
Deinonychus, 50
Depression: adolescent, 156; biogenic amine theory of, 167; genetic, 127–132; major, 39; serotonin theory of, 168
Destigmatization, 160–164
Dexamethasone suppression test (DST), 167
Diagnostic and Statistical Manual of Mental Disorders (DSM), 22, 23, 25, 28, 29, 44, 118; DSM-III, 24; DSM-IV, 6, 9, 10, 18, 22
Diagnostic classification, 21
Diagnostic disorder, 23–28; and cultural bias, 29–30; as flawed extension of medical model, 30; and labeling, 27–28; and reliability, 24–25; and validity, 25–26
Dialectical behavior therapy (DBT), 44
Diathesis-stress paradigm, 130
Disability, paradigm of, 198
Disrupted homeostasis, 169
Division of Clinical Psychology, 39
Dodo bird verdict, 32, 33, 38, 42, 43, 51
Dopamine, 166, 167
Dose-effect relationship, 108
“Dose-Effect Relationship in Psychotherapy” (American Psychologist), 84
Drug companies, 29
Drug Enforcement Administration, 148
Drug research, four flaws of, 152–156
DST. See Dexamethasone suppression test (DST)

E
Eating disorders, 39
Eclecticism, 119, 120
Effectiveness: and competence, 13; Human Affairs International study of, 32; in medical health provider organizations, 13; proof of, 12; psychotherapy, 8; and Treatment of Depression Collaborative Research Project, 26
Elavil, 152
Eli Lilly and Company, 154, 155
Emma (client), 201–211
Emotionally focused therapy (EFT), 42–44
“Emperor’s New Drugs” (Kirsch, Moore, Scoboria, and Nicholls), 172
Epinephrine, 166
ESPN, 70
Ethical codes, 13
Evaluation, 187
Evidence-based practice, 3, 7, 21; and alliance factors, 35–37; and client factors, 34–35; and model or technical factors, 37–38; myth of, 31–47; reliability and validity of, 46–47; as ultimate silver bullet, 38–47
Expectancy factors, 37
Expertise, 190

F
Family Counseling Office (Vestfold, Norway), 108
Family Therapy Magazine, 149
FDA. See Federal Drug Administration (FDA)
FDA Talk Paper (FDA Press Office), 155, 162
Federal Drug Administration (FDA), 150, 154, 155, 162, 172
Federal Drug trials, 39
First-session formula task, 143
Fluoxetine (Prozac), 151, 152, 155, 156. See also Medication
French psychiatrists, 166
From Placebo to Panacea (Greenberg and Fisher), 156

G
Genetic depression, 127–132
Geodon, 161, 202
GlaxoSmithKline, 162
Global Assessment Scale, 152
Goals, 192–194
Godzilla, 49, 50

H
Hamilton Depression Scale, 152, 174
Harding study, 27
Harvard University, 81
Hay Group, 3
Heart and Soul of Change (Hubble, Duncan, and Miller), 34
Helping Alliance Questionnaire II (HAQ), 90, 92
Heraclites, 56, 57
Heroic stories: creating new, 56–63; expanding change into, 58–63; listening for, 52–55
HIV, 67
Hollywood, 82
Homosexuality, 29
Human Affairs International, 32

I
Imipramine, 168
IMS Health, 148, 149, 164
India, 165
Interpretation, 185
Intervention, 194–198
Interview, conversation versus, 122
I-statement strategies, 195
### 264 SUBJECT INDEX

#### J
- Jan and Mark (clients), 182–199
- Joan (client), 59–63
- *Journal of Consulting and Clinical Psychology*, 6

#### K
- Killer D’s, 35, 127
- Kim (client), 125–126

#### L
- Lilly. See Eli Lilly and Company
- Linda (client), 111, 112
- Linear causality, 187–188
- Linear regression, 110. See also Simple linear regression (SLR)
- Liz and Bob (clients), 142–145

#### M
- Magic pill, myth of, 9. See Medication
- Major depressive disorder (MDD), 155, 162
- Manuals, 41
- Maria (client), 16–18, 27, 53–55
- Massachusetts Medicaid program, 148
- MDD. See Major depressive disorder (MDD)
- Medicaid, 163
- Medical model, 7, 8, 10; diagnostic disorder as extension of; 30; myth of, 21–48; relational model versus, 19; script for, 180
- Medication: and antidepressants for children, 151–152; and bioamine theories, 167–169; and biochemical imbalance, 165–167; and demystifying magic pill, 170–173; and destigmatization, 160–164; and ethics of medicating children, 148–164; and medicated nation, 164–175; overview of, 147–148; versus therapy, 173–175
- Medicine and Healthcare Products Regulatory Agency (United Kingdom; MHRA), 162
- Mental disease, concept of, 21
- Mental health care benefits, 82
- Mental health practice: and client-directed, outcome-informed therapy assessment, 186–192; future of, 3–10; medical model applied to, 5, 6, 8; models and, 184–186; neurology of, 179–181; and paradigm of disability, 198–199; and pathology, 181–182; relational model for, 19; and responsibility, 199–200; state of, 1–3
- Mental health practitioners, 1, 2; ethical codes of, 13
- Mental Research Institute (MRI), 121, 127
- *Merriam-Webster’s Collegiate Dictionary*, 184, 195
- Methylphenidate (Ritalin), 148, 149. See also Medication
- Mike (client), 75–78
- Models, 37–38, 184–186
- Molly (client), 49, 63, 71, 79
- Montana, 50
- MRI. See Mental Research Institute (MRI)
- MTA Cooperative Group, 157, 158, 175
- Multimodal Treatment Study of Children with ADHD (MTA Cooperative Group), 157
- Multisystemic therapy (MST), 43, 44

#### N
- Narcotics Anonymous (NA), 65, 67
- National Action Agenda for Children’s Mental Health (NAACMH), 163
- National Anxiety and Depression Awareness Day, 6
- National Association of Rights Protection and Advocacy, 213–214
- National Association of Social Workers (NASW), 11
- National Institute of Mental Health (NIMH), 22, 25, 26, 149, 161, 173
- *New England Journal of Medicine*, 7, 154
- New Freedom Commission of Mental Health, 29
SUBJECT INDEX

New York Times, 63
Nicotine dependence, 39
NIMH. See National Institute of Mental Health (NIMH)
Noradrenaline, 166, 167
Norway, 93, 108, 111

O
One Flew Over the Cuckoo's Nest (Kesey), 181
Outcome: and future, 117–118; informed, becoming, 12–16; prediction of, 26; from process to, 83–85; research, and Erickson’s observations, 11, 12; successful, versus competent service, 19; tracking, 86–96
Outcome management, 15
Outcome Questionnaire 45.2 (OQ), 86–88, 92, 94
Outcome Rating Scale (ORS), 87–89, 91, 110–113, 222; in action, 94–96; and checking for change, 102–107; and conversation, 124; and drug research, 156; experimental version of, for children, 224; experimental version of, for young children, 226; incorporating, in first meeting, 99–100; introduction of, in first meeting, 98–99; reliability, validity, and feasibility of, 91–94

P
Paroxetine, 156, 162
Participation, client, 36, 182
Pat (client), 128–132
Pathology, 8, 29; and pathological labels, 15; swimming in, 181–182
Paxil, 162, 164, 165
Pedophila, 138–142
Peer ratings, 14
Personal construct theory, 120
Pharmaceutical marketing, 163–165
Pittsburgh, Pennsylvania, 174
Placebo, 151–156, 171, 172, 175
Platelet-binding assays, 168
Pretreatment change, 56
Problem focus, 189
Project MATCH, 89
Prozac (fluoxetine), 151–155, 161, 164, 171, 175, 181. See also Medication
Psychiatric diagnoses, myth of, 9, 23–30; and diagnostic disorder, 23–28
Psychopharmacology, 166
Psychosis, 166
Psychotherapy Bulletin, 213
Psychotropic medications, 148, 149, 160, 164. See also Medication
Psychotherapy, and medical model, 5

R
Randomized clinical trial (RCT), 22, 39–41, 46
RCI. See Reliable change index (RCI)
RCT. See Randomized clinical trial (RCT)
Relational bond, cementing, 64–65
Relationship factors, 35–37
Reliability, and diagnosis, 24–25
Reliable change index (RCI), 110, 111
Religious beliefs, 78, 115
Reserpine, 165–168
Risperdal, 148, 164
Ritalin (methylphenidate), 148, 156, 216.
See also Medication
Robyn (client), 115–117

S
Sam (client), 65–68
Sarah (client), 69, 70
Schizophrenia, 27, 28, 165–167, 201, 202, 213, 214
Science, 27
Sean (client), 51, 56
Serotonin, 167, 168
Seroxat (paroxetine), 162
Session curve, change by, 108–110, 109fig.4.2
Session Rating Scale (SRS), 89–91, 223; in action, 94–96; and checking for change, 102–107; and conversation, 124; experimental version of, for
Session Rating Scale (SRS) (continued)
- children, 225; experimental version of, for young children, 227; incorporating, 101–102; introducing, 100–101; reliability, validity, and feasibility of, 91–94
- Session-by-session evaluation, 16
- Silver-bullet cure, myth of. See Evidence-based practice
- Simple linear regression (SLR), 110–111; in action, 111–112
- SLR. See Simple linear regression (SLR)
- SSRIs, 148, 151, 152, 154–156, 161, 162, 167, 168, 171. See also Medication
- Stacy (client), 132–138
- Star Trek (science-fiction series), 5, 10
- Steven (client), 113–115
- Stimulants, 148, 149, 160; and children, 156–160. See also Medication

T
- Talk therapy approach, 7
- Television, 82
- The Guardian, 162
- Theory, formal versus informal, 121, 122
- Theory-driven practice, client-directed versus, 19
- Therapeutic alliance, 72/fig.3.1
- Therapeutic relationship, 16
- Therapist allegiance, 122
- Therapy: consumer tips for, 219–212; client-directed, outcome-informed therapy’s goals for, 192–194; drugs versus, 173–175; factors arguing for change in, 33/fig.2.1; from process to outcome in, 83–85; and randomized clinical trials, 41; tailoring tasks of, 70–71
- Third-party payers, 15
- Treatment of Depression Collaborative Research Project (TDCRP), 26, 32, 36, 42, 71, 72, 89
- Tricyclic antidepressants, 148, 151.
  See also Medication
- Tylenol, 51

U
- University of Southern Mississippi, 213
- “Using the Outcome Rating Scale with Couples” (Anker and Duncan), 109/fig.4.2
- Utilization (Erickson), 121

V
- Validation, 65, 131
- Validity, in diagnosis, 25–26
- Valium, 180
- Vermont hospitals, 27

W
- Working Alliance Inventory (WAI), 90, 94
- World Health Organization, 168
- World Series (1999), 165
- World War II, 21

X
- Xanax, 180

Y
- Yale University, 50
- Young Child Outcome Rating Scale (YCORS), 226
- Young Child Session Rating Scale (YCRS), 227

Z
- Zelmid (zimelidine), 167
- Zoloft, 6, 7, 161, 164, 165, 170
- Zyprexa, 164